Hjem › Kræft (alle typer) › Texas › Irving
Kræft (alle typer) kliniske forsøg i Irving, TX
15 studier for Kræft (alle typer) søger deltagere på steder i og omkring Irving (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.
Officiel studietekst (engelsk)
Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →
REC-7735 in Participants With Solid Tumors
RekruttererFase 1/2
- NEXT Oncology - Dallas, Irving
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
RekruttererFase 1
- NEXT Dallas, Irving
Registry Study for Radiation Therapy Outcomes
RekruttererObservationsstudie
- Texas Center for Proton Therapy, Irving
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
RekruttererFase 3
- US Oncology Research Investigational Products Center, Irving
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RekruttererFase 1/2
- NEXT Dallas, Irving
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
RekruttererFase 1
- NEXT Oncology ( Site 0051), Irving
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
RekruttererFase 1/2
- NEXT Oncology ( Site 1012), Irving
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
RekruttererFase 1/2
- NEXT Oncology Dallas, Irving
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
RekruttererFase 1
- NEXT Oncology Dallas, Irving
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
RekruttererFase 1
- NEXT Dallas, Irving
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
RekruttererFase 1
- NEXT Dallas, Irving
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RekruttererFase 1/2
- NEXT Oncology, Irving
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
RekruttererFase 1
- NEXT Oncology, Irving
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RekruttererFase 1/2
- NEXT Dallas, Irving
Registry Study for Proton Therapy Clinical Outcomes and Long-Term Follow-up
RekruttererObservationsstudie
- Texas Center for Proton Therapy, Irving
Kræft (alle typer) forsøg i andre byer
- Houston, TX121 studier
- New York City, NY110 studier
- Boston, MA86 studier
- Los Angeles, CA73 studier
- Nashville, TN65 studier
- Philadelphia, PA59 studier
- Durham, NC58 studier
- Washington, DC58 studier
- Chicago, IL51 studier
- Seattle, WA49 studier
- Atlanta, GA49 studier
- Arlington, VA48 studier
Andre studier i Irving
- Ikke-småcellet lungecancer22 studier
- Colorektal kræft13 studier
- Metastatisk cancer11 studier
- Bugspytkirtelkræft7 studier
- Mavekræft7 studier
- Pladecellekræft i hoved og hals6 studier
- Brystkræft6 studier
- Småcellet lungekræft6 studier
- Lungecancer6 studier
- Ægstockræft5 studier
- Livmoderslimhindekræft4 studier
- Prostatakræft4 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.